Format

Send to

Choose Destination
Curr Cancer Drug Targets. 2012 Jul;12(6):693-702.

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

Author information

1
Department of Oncological Immunology, Istituto per lo Studio e la Cura dei Tumori "Pascale", Naples, Italy.

Abstract

BACKGROUND:

Almost 30% of the sunitinib-treated patients for metastatic renal carcinoma (mRCC) do not receive a clinical benefit. Convincing evidences demonstrated a cross talk between the VEGF and CXCR4 pathways. It was hypothesized that CXCR4 expression in primary renal cancer could predict sunitinib responsiveness.

PATIENTS AND METHODS:

In this exploratory study sixty-two mRCC patients receiving sunitinib as first-line treatment were evaluated for CXCR4 expression through immunohistochemistry (IHC). Correlations between CXCR4 expression, baseline patients and tumour characteristics were studied by contingency tables and the chi-square test. Univariable analysis was performed with the log-rank test, and the Cox model was applied for multivariable analysis.

RESULTS:

The objective response rate of sunitinib first-line therapy was 35.5% (22/62) with a disease control rate (response and stable disease) of 62.9% (39/62). CXCR4 expression was absent/low in 30 (48.4%), moderate in 17 (27.4%), and high in 15 (24.2%) tumors respectively. Low or absent CXCR4 expression predicted response to sunitinib therapy. Moreover, Fuhrman grading and concomitant, CXCR4 and Fuhrman grading, strongly predicted sunitinib first line therapy responsiveness on progression-free survival and overall survival.

CONCLUSIONS:

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

PMID:
22463589
DOI:
10.2174/156800912801784820
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center